Therapeutic area intelligence for HDAC Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Amneal →

Recent signals(2)

RegulatoryAugust 13, 2026

FDA Approval Process for Romidepsin Application ANDA219099

The FDA is reviewing ANDA219099 for Romidepsin submitted by Amneal, with a standard review priority.

StrategyJuly 22, 2026

FDA Grants Approval for Romidepsin ANDA219099 by Amneal

The FDA has granted approval for Amneal's ANDA219099 for Romidepsin, indicating a successful submission.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.